van de Ven C, Ishizawa L, Law P, Cairo M S
Division of Hematology/Oncology, Children's Hospital of Orange County, Orange, CA 92668, USA.
Exp Hematol. 1995 Nov;23(12):1289-95.
Hematopoietic progenitor cells in human umbilical cord blood have been shown to be effective sources for hematopoietic reconstitution following myeloablative therapy. Unfortunately, the use of cord blood (CB) is limited by the number of progenitor cells necessary to reconstitute the older child or adult. We studied the expansion of an isolated population of CD34+ cells from CB and adult bone marrow (ABM) after 1 to 3 weeks in culture when stimulated with lineage-nonspecific (IL-11 and/or SLF) and lineage-specific (G-CSF or GM-CSF) cytokines. IL-11 and SLF alone or in combination did not enhance expansion of CB CD34+ stem cells. With combinations of IL-11, SLF, and G-CSF or GM-CSF, however, after 1, 2, or 3 weeks in culture, WBC expansion was significantly greater in CB vs. ABM (p < 0.05). At all time points, expanded CB consistently demonstrated a significant increase in cell production and myeloid differentiation when compared to ABM. To assess the proliferative potential of the expanded cultures, cells were recovered from the expansion cultures, plated in methylcellulose, and evaluated for CFU-GM and CFU-Meg colony formation. After 2 weeks in culture, a significant increase in CFU-GM colony formation in CB vs. ABM was demonstrated with SLF (p < 0.001), IL-11 plus SLF (p < 0.0005), and IL-11 plus SLF plus G-CSF (p < 0.004). Significantly greater CFU-Meg formation was also seen in CB vs. ABM cells plated after expansion with IL-11 plus SLF plus G-CSF (weeks 1 and 2) or IL-11 plus SLF plus GM-CSF (week 1) (p < 0.05). Finally, immunophenotyping was performed on CB cultures on days 0 and 14, and although a significant reduction of the percentage of progenitors (CD34+/38+/38-/DR+) was seen, their absolute numbers were maintained. (Data for ABM was not available). This study suggests that IL-11, when combined with SLF and more lineage-specific cytokines, can effectively maintain primitive multipotential progenitors and stimulate the differentiation of more committed precursors in CB compared to ABM.
人脐带血中的造血祖细胞已被证明是清髓性治疗后造血重建的有效来源。不幸的是,脐带血(CB)的使用受到重建大龄儿童或成人所需祖细胞数量的限制。我们研究了在培养1至3周后,用谱系非特异性(IL-11和/或SLF)和谱系特异性(G-CSF或GM-CSF)细胞因子刺激时,从CB和成人骨髓(ABM)中分离出的CD34+细胞群体的扩增情况。单独使用IL-11和SLF或两者联合使用均未增强CB CD34+干细胞的扩增。然而,使用IL-11、SLF与G-CSF或GM-CSF的组合时,培养1、2或3周后,CB中的白细胞扩增明显大于ABM(p<0.05)。在所有时间点,与ABM相比,扩增后的CB始终显示细胞产量和髓系分化显著增加。为了评估扩增培养物的增殖潜力,从扩增培养物中回收细胞,接种于甲基纤维素中,并评估CFU-GM和CFU-Meg集落形成情况。培养2周后,使用SLF(p<0.001)、IL-11加SLF(p<0.0005)以及IL-11加SLF加G-CSF(p<0.004)时,CB中CFU-GM集落形成较ABM有显著增加。在用IL-11加SLF加G-CSF(第1周和第2周)或IL-11加SLF加GM-CSF(第1周)扩增后接种的CB细胞中,与ABM细胞相比,也观察到显著更多的CFU-Meg形成(p<0.05)。最后,在第0天和第14天对CB培养物进行免疫表型分析,尽管祖细胞(CD34+/38+/38-/DR+)百分比显著降低,但其绝对数量保持不变。(ABM的数据不可用)。本研究表明,与ABM相比,IL-11与SLF以及更多谱系特异性细胞因子联合使用时,能有效维持CB中原始多能祖细胞,并刺激更定向前体细胞的分化。